- Epoxomicin
-
- $15.00 / 1KG
-
2021-07-13
- CAS:134381-21-8
- Min. Order: 1KG
- Purity: 99%+ HPLC
- Supply Ability: Monthly supply of 1 ton
- Epoxomicin
-
- $15.00 / 1KG
-
2021-07-10
- CAS:134381-21-8
- Min. Order: 1KG
- Purity: 99%+ HPLC
- Supply Ability: Monthly supply of 1 ton
- EPOXOMICIN
-
- $1.00 / 1KG
-
2020-01-05
- CAS:134381-21-8
- Min. Order: 1KG
- Purity: 99%
- Supply Ability: 1kg-1000kg
|
| | EPOXOMICIN Basic information |
| Product Name: | EPOXOMICIN | | Synonyms: | BU-4061T;EPOXOMICIN, SYNTHETIC;EPOXOMICIN;(2R)-2-[ACETYL-(N-METHYL-L-ISOLEUCYL)-L-ISOLEUCYL-L-THREONYL-L-LEUCYL]-2-METHYLOXIRANE;n-acetyl-n-methyl-l-isoleucyl-l-isoleucyl-n-[(1s)-3-methyl-1-[[(2r)-2-methyloxiranyl]carbonyl]butyl]-l-threoninamide;Aids010837;Aids-010837;L-Threoninamide, N-acetyl-N-methyl-L-isoleucyl-L-isoleucyl-N-[(1S)-3-methyl-1-[[(2R)-2-methyloxiranyl]carbonyl]butyl]- | | CAS: | 134381-21-8 | | MF: | C28H50N4O7 | | MW: | 554.72 | | EINECS: | | | Product Categories: | peptides;ProteasomeInhibitors | | Mol File: | 134381-21-8.mol |  |
| | EPOXOMICIN Chemical Properties |
| Melting point | 107-109° | | alpha | D24.5 -66.1 ± 0.4° (c = 0.5 in MeOH) | | Boiling point | 795.7±60.0 °C(Predicted) | | density | 1.117±0.06 g/cm3(Predicted) | | storage temp. | -20°C | | solubility | Soluble in DMSO (up to 10 mg/ml). | | pka | 13.02±0.46(Predicted) | | form | solid | | color | White | | Stability: | Stable for 2 years from date of purchase as supplied. Solutions in DMSO may be stored at -20° for up to 2 months. | | InChIKey | DOGIDQKFVLKMLQ-JTHVHQAWSA-N | | SMILES | CC[C@H](C)[C@H](NC(=O)[C@H]([C@@H](C)CC)N(C)C(C)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(=O)[C@@]1(C)CO1 |
| WGK Germany | 3 | | HS Code | 29299090 | | Storage Class | 11 - Combustible Solids |
| | EPOXOMICIN Usage And Synthesis |
| Description | Epoxomicin (134381-21-8) is a potent, selective and cell permeable irreversible inhibitor of the 20S proteasome.1 It does not inhibit non-proteasomal proteases such as papain, chymotrypsin, trypsin, calpain and cathepsin B at concentrations up to 50 μM.1 Epoxomicin was isolated from Actinomycete strain Q996-17 and displayed in vivo antitumor activity against B16 melanoma cells.2 Epoxomicin caused a progressive model of Parkinson’s disease in various systems.3,4,5 This model has been disputed.6,7 | | Uses | In studies of proteasome biology. | | Uses | Epoxomicin has been used:
- as an ubiquitin–proteosome system (UPS) inhibitor in pheochromocytoma PC12 cells
- as a proteasome inhibitor in mammary epithelial MCF-10A cells
- as a proteasome inhibitor in chymotryptic assay in cardiomyocytes
| | Definition | ChEBI: A tripeptide consisting of an Ile-Ile-Thr-NH2 sequence N-substituted on the threonamide amidic nitrogen with a (2S)-4-methyl-1-[(2R)-2-methyloxiran-2-yl]-1-oxopentan-2-yl group and with acetyl and meth
l groups on the nitrogen of the isoleucine residue distal to the threonamide; a naturally occurring selective proteasome inhibitor with anti-inflammatory activity. | | General Description | Epoxomicin is a linear peptide consisting of a threonine or serine residue with α′, β′-epoxyketonederived from leucine or a γ,δ-dehydroleucine. It is a natural product isolated fromActinomycessp., and is a cell-permeable, potent, selective and irreversible proteasome inhibitor. | | Biochem/physiol Actions | Epoxomicin binds covalently to the catalytic subunits of proteasome. It forms an adduct with target proteins. It inhibits chymotrypsin-like activity of the proteasome. Epoxomicin also inhibits the nuclear factor κ light chain enhancer of activated B cells (NF-κB) mediated proinflammatory signalling pathway. It is also a potent antitumor and anti-inflammatory agent. | | target | 20S proteasome | | storage | +4°C | | References | [1] L MENG. Epoxomicin, a potent and selective proteasome inhibitor, exhibits in vivo antiinflammatory activity.[J]. Proceedings of the National Academy of Sciences of the United States of America, 1999, 96 18: 10403-10408. DOI:10.1073/pnas.96.18.10403
[2] M HANADA. Epoxomicin, a new antitumor agent of microbial origin.[J]. Journal of Antibiotics, 1992, 45 11: 1746-1752. DOI:10.7164/antibiotics.45.1746
[3] KEVIN ST. P. MCNAUGHT PHD. Systemic exposure to proteasome inhibitors causes a progressive model of Parkinson’s disease[J]. Annals of Neurology, 2004, 56 1: 149-162. DOI:10.1002/ana.20186
[4] HIDEAKI MATSUI. Proteasome inhibition in medaka brain induces the features of Parkinson’s disease[J]. Journal of Neurochemistry, 2010, 115 1: 178-187. DOI:10.1111/j.1471-4159.2010.06918.x
[5] M J METCALFE M E F P Q Huang. Coordination between proteasome impairment and caspase activation leading to TAU pathology: neuroprotection by cAMP[J]. Cell Death & Disease, 2012, 3 6: e326-e326. DOI:10.1038/cddis.2012.70
[6] JEFFREY H. KORDOWER PHD. Failure of proteasome inhibitor administration to provide a model of Parkinson’s disease in rats and monkeys[J]. Annals of Neurology, 2006, 60 2: 264-268. DOI:10.1002/ana.20935
[7] WENJIE XIE. Proteasome inhibition modeling nigral neuron degeneration in Parkinson’s disease[J]. Journal of Neurochemistry, 2010, 115 1: 188-199. DOI:10.1111/j.1471-4159.2010.06914.x |
| | EPOXOMICIN Preparation Products And Raw materials |
|